These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 16778291)

  • 41. Bronchodilators in COPD: impact of beta-agonists and anticholinergics on severe exacerbations and mortality.
    Salpeter SR
    Int J Chron Obstruct Pulmon Dis; 2007; 2(1):11-8. PubMed ID: 18044061
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Optimal treatment of chronic obstructive pulmonary disease: the search for the magic combination of inhaled bronchodilators and corticosteroids.
    Criner GJ
    Ann Intern Med; 2007 Apr; 146(8):606-8. PubMed ID: 17438320
    [No Abstract]   [Full Text] [Related]  

  • 43. Economic evaluations of fluticasone-propionate/salmeterol combination therapy for chronic obstructive pulmonary disease: a review of published studies.
    Roberts MH; Borrego ME; Kharat AA; Marshik PL; Mapel DW
    Expert Rev Pharmacoecon Outcomes Res; 2016; 16(2):167-92. PubMed ID: 26839089
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Translating Pharmacometrics to a Pharmacoeconomic Model of COPD.
    Slejko JF; Willke RJ; Ribbing J; Milligan P
    Value Health; 2016 Dec; 19(8):1026-1032. PubMed ID: 27987629
    [TBL] [Abstract][Full Text] [Related]  

  • 45. "Show me the money": a fair criticism of economic studies on inhaled bronchodilators for COPD.
    Kostikas K; Bouros D
    BMC Pulm Med; 2010 Sep; 10():48. PubMed ID: 20843312
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Chronic obstructive pulmonary disease in the elderly: an update on pharmacological management.
    Dzierba AL; Jelic S
    Drugs Aging; 2009; 26(6):447-56. PubMed ID: 19591519
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Treatment of COPD: from pharmacological to instrumental therapies.
    Alifano M; Cuvelier A; Delage A; Roche N; Lamia B; Molano LC; Couderc LJ; Marquette CH; Devillier P
    Eur Respir Rev; 2010 Mar; 19(115):7-23. PubMed ID: 20956161
    [No Abstract]   [Full Text] [Related]  

  • 48. Systematic review of models used in economic analyses in moderate-to-severe asthma and COPD.
    Einarson TR; Bereza BG; Nielsen TA; Van Laer J; Hemels ME
    J Med Econ; 2016; 19(4):319-55. PubMed ID: 26535917
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Large trials, new knowledge: the changing face of COPD management.
    De Soyza A; Calverley PM
    Eur Respir J; 2015 Jun; 45(6):1692-703. PubMed ID: 25792640
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Roflumilast as add-on therapy to conventional inhalers in COPD: a cost-effectiveness analysis.
    Antoniu SA
    J Comp Eff Res; 2012 Jul; 1(4):315-7. PubMed ID: 24237465
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Economic burden of chronic obstructive pulmonary disease. Impact of new treatment options.
    Friedman M; Hilleman DE
    Pharmacoeconomics; 2001; 19(3):245-54. PubMed ID: 11303413
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Economic impact of pulmonary drugs on direct costs of stable chronic obstructive pulmonary disease.
    Izquierdo-Alonso JL; de Miguel-Díez J
    COPD; 2004; 1(2):215-23. PubMed ID: 17136989
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmaceutical treatment status of patients with COPD in the community based on medical Internet of Things: a real-world study.
    Wu P; Jiang YQ; Si FL; Wang HY; Song XB; Sheng CF; Xu X; Li F; Zhang J
    NPJ Prim Care Respir Med; 2024 May; 34(1):10. PubMed ID: 38729942
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Assessing the determinants of the potential for cost-effectiveness over time: the empirical case of COPD.
    Camejo RR; McGrath C; Herings R; Starkie H; Rutten F
    Value Health; 2013; 16(2):426-33. PubMed ID: 23538195
    [TBL] [Abstract][Full Text] [Related]  

  • 55. 2. Advances in pharmacotherapy for COPD.
    Ichinose M
    Intern Med; 2007; 46(2):81-4. PubMed ID: 17220603
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Long-acting bronchodilators are the first-choice option for the treatment of stable COPD.
    Cazzola M; Matera MG
    Chest; 2004 Jan; 125(1):9-11. PubMed ID: 14718412
    [No Abstract]   [Full Text] [Related]  

  • 57. Suboptimal medical therapy in COPD: exploring the causes and consequences.
    Ramsey SD
    Chest; 2000 Feb; 117(2 Suppl):33S-7S. PubMed ID: 10673472
    [TBL] [Abstract][Full Text] [Related]  

  • 58. New clinical insights into chronic obstructive pulmonary disease and their implications for pharmacoeconomic analyses.
    Mapel DW; Roberts MH
    Pharmacoeconomics; 2012 Oct; 30(10):869-85. PubMed ID: 22852587
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Medicare Part D Plans' Coverage and Cost-Sharing for Acute Rescue and Preventive Inhalers for Chronic Obstructive Pulmonary Disease.
    Tseng CW; Yazdany J; Dudley RA; DeJong C; Kazi DS; Chen R; Lin GA
    JAMA Intern Med; 2017 Apr; 177(4):585-588. PubMed ID: 28241217
    [No Abstract]   [Full Text] [Related]  

  • 60. Cost Evaluation of Inhaler Therapies Used in Respiratory Diseases: 1998--2015 Period in Turkey.
    Bayar B; Kutkan NU; Şafak Yılmaz E; Tolun Ç; Doğan E; Atikeler EK; Vural EH; Babacan S; Karabekmez N; Beyan A; Vural İM; Oğuzülgen İK; Bektemür G; Malhan S; Kahveci R; Altın S; Alkan A; Eroğlu H; Gürsöz H
    Value Health Reg Issues; 2017 Sep; 13():31-38. PubMed ID: 29073985
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.